QQ客服 官方微博 反馈留言

浏览/检索结果: 共11条，第1-10条 帮助 限定条件 发表日期：2021     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang 收藏  |  浏览/下载：62/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance   A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors 期刊论文 TRANSLATIONAL LUNG CANCER RESEARCH, 2021 作者:  Xu, Xiaoling;  Wang, Ding;  Chen, Wei;  Li, Na;  Suwinski, Rafal 收藏  |  浏览/下载：42/0  |  提交时间：2022/02/14 Immune checkpoint inhibitor (ICI)  non-small cell lung cancer (NSCLC)  peripheral blood lymphocyte subsets   Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance (vol 19, 90, 2020) 期刊论文 MOLECULAR CANCER, 2021, 卷号: 20, 期号: 1, 页码: 1 作者:  Zhang, Tao;  Qu, Rong;  Chan, Shingpan;  Lai, Mengzhen;  Tong, Linjiang 收藏  |  浏览/下载：58/0  |  提交时间：2021/11/04 Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance 期刊论文 Molecular Cancer, 2021, 卷号: 20, 期号: 1 作者:  Zhang,Tao;  Qu,Rong;  Chan,Shingpan;  Lai,Mengzhen;  Tong,Linjiang 收藏  |  浏览/下载：41/0  |  提交时间：2021/11/04 Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance 期刊论文 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 卷号: 202 作者:  Li, Na;  Mao, Weimin;  Gao, Yun;  Wang, Ding;  Song, Zhengbo 收藏  |  浏览/下载：49/0  |  提交时间：2021/08/31 Lung cancer  EGFR-TKI  Resistance  Pleural effusion  Metabolomics  Biomarker   Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9 作者:  Liu, Lu;  Li, Wei;  Yang, Le;  Guo, Zi-tao;  Xue, Hao 收藏  |  浏览/下载：78/0  |  提交时间：2021/08/17 almonertinib  itraconazole  rifampicin  drug metabolism  drug interaction  CYP3A  P-gp  pharmacokinetics   Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun 收藏  |  浏览/下载：69/0  |  提交时间：2021/06/11 metabolism  mass balance  distribution  covalent binding  furmonertinib   Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:  Meng, Jian;  Zhang, Hua;  Bao, Jing-jing;  Chen, Zhen-dong;  Liu, Xiao-yun 收藏  |  浏览/下载：71/0  |  提交时间：2021/06/11 metabolism  mass balance  distribution  covalent binding  furmonertinib   Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu 收藏  |  浏览/下载：19/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers 期刊论文 INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8 作者:  Zhu, Yun-ting;  Zhang, Yi-fan;  Jiang, Jin-fang;  Yang, Yong;  Guo, Li-xia 收藏  |  浏览/下载：27/0  |  提交时间：2021/05/24 Alflutinib  Rifampicin  CYP3A4  AST5902  Drug-drug interaction